about
Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combinatPopulation Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population.Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model.Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population.Distribution of xanthine oxidase activity in a Nigerian population.Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.In vivo antimalarial evaluation of MAMA decoction on Plasmodium berghei in mice.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.Establishment of a biobank and pharmacogenetics database of African populations.Quality of artemisinin-based antimalarial drugs marketed in Nigeria.Thiopurine S-methyltransferase activity in Nigerians: phenotypes and activity reference values.Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteersInter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?Liquid chromatographic analysis of chloroquine and desethylchloroquine in human plasma, saliva and urineAfrican Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in AfricaMetabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparationColumn liquid chromatographic analysis of quinine in human plasma, saliva and urinePharmacogenomics in the Nigerian population: the past, the present and the future
P50
Q35960735-3017AD57-3FA5-4AD1-8CDD-FE83D4C4E4BAQ38724254-922A6126-8C61-4EA3-A953-9ACA2AE0053BQ38828031-E7ADD92D-C0BC-426C-9A09-6B1653BFA4E0Q38946020-C696C57F-9801-4340-974E-960AAFC68B28Q40723535-B9C3885F-41FF-4DCA-B3A4-C4CA8F6EE197Q40812008-AF7086C4-A749-4BFB-8388-75ED239652B4Q40978224-6EEFCE99-16FA-4F24-9A1B-4F02AC64FC26Q41326094-B045F76B-A128-4F6F-8DB7-5CF7A0DDD914Q42708215-E56371C0-4F88-4870-96A2-9694F72876DBQ46460183-B1F3280E-36FF-44B6-9A52-AE905CB8BEE7Q46474927-2668CFDD-41FE-45BC-9517-81B7FBDA70EFQ46573709-2D659751-AD16-4741-BE51-0D2012172524Q47993043-C462E434-73B8-49E5-87F1-58EDE685D629Q49387116-2094C779-F169-4C5B-BEB1-C49F16108A8FQ50265016-229DF325-191A-4310-A29E-DC4E5B4F1986Q50568163-B7DE9526-1661-4D02-8C95-35CF8A030B07Q56376481-1777073C-2776-4345-B49B-B1CECB50AD95Q60630376-CEBEBAAE-6EDA-40CC-BE6D-3FB7B290DAFDQ69620829-2E7494B4-6ADC-4D4D-B640-4E166263F62CQ69682607-66DEBF42-FED3-4A04-9F05-DD8A017F275AQ72458270-1D880785-0A2D-470D-B75D-CD8C58CFDD7FQ72932488-D9E12302-7C97-4238-A632-383546A85259Q92896604-077C6BBA-6137-4272-B3F8-3DB2C67876D8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Oluseye Bolaji
@ast
Oluseye Bolaji
@en
Oluseye Bolaji
@es
Oluseye Bolaji
@nl
type
label
Oluseye Bolaji
@ast
Oluseye Bolaji
@en
Oluseye Bolaji
@es
Oluseye Bolaji
@nl
prefLabel
Oluseye Bolaji
@ast
Oluseye Bolaji
@en
Oluseye Bolaji
@es
Oluseye Bolaji
@nl
P106
P31
P496
0000-0002-8295-7150